Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Change in Accured Expenses (2016 - 2025)

Iradimed (IRMD) has disclosed Change in Accured Expenses for 13 consecutive years, with -$150000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Change in Accured Expenses rose 76.22% to -$150000.0 in Q1 2025 year-over-year; TTM through Sep 2025 was -$759123.0, a 156.62% decrease, with the full-year FY2024 number at -$100000.0, down 140.0% from a year prior.
  • Change in Accured Expenses was -$150000.0 for Q1 2025 at Iradimed, up from -$609123.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $831699.0 in Q4 2023 to a low of -$1.3 million in Q1 2023.
  • A 5-year average of $56079.0 and a median of -$1.0 in 2022 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 71600800.0% in 2023; the steepest drop was 15602.45% in 2023.
  • Iradimed's Change in Accured Expenses stood at $400574.0 in 2021, then dropped by 20.53% to $318353.0 in 2022, then skyrocketed by 161.25% to $831699.0 in 2023, then crashed by 173.24% to -$609123.0 in 2024, then soared by 75.37% to -$150000.0 in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Change in Accured Expenses are -$150000.0 (Q1 2025), -$609123.0 (Q4 2024), and $379527.0 (Q3 2024).